HUTCHMED Highlights Data to be Presented at ASCO
HUTCHMED to present clinical data for savolitinib, fruquintinib and surufatinib at ASCO Annual Meeting.
vs expectations: met primary endpoint
- Savolitinib ORR in gastric cancer (IRC-assessed) 32.3% (95%CI: 21.2%, 45.1%)
- Savolitinib DCR in gastric cancer 63.1%
- Savolitinib median PFS 4.0 (95%CI: 2.6, 5.0) months
- Savolitinib median DoR 9.7 (95%CI: 3.7, 18.5) months
- Savolitinib median TTR 1.4 months
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
Hong Kong, Shanghai & Florham Park, NJ - Friday, May 22, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate ("ORR") per RECIST 1.1, as assessed by the Independent Review Committee ("IRC"). As of the data cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included the IRC-assessed disease control rate (DCR) of 63.1%, median time to response (TTR) of 1.4 months, median duration of response (DoR) of 9.7 (95%CI: 3.7, 18.5) months, and median progression-free survival (PFS) of 4.0 (95%CI: 2.6, 5.0) months, respectively. The data supported the New Drug Application (NDA) submission to the China National Medical Products Administration (NMPA), which was accepted and granted priority review in December 2025.
Additionally, further analyses of the fruquintinib's FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, as well as investigator-initiated studies of fruquintinib and surufatinib spanning across a diverse range of potential tumor indications will be presented.
Details of the presentations, including links to available abstracts, are as follows:
| Abstract title | Presenter / Lead Author | Presentation details |
| SPONSORED STUDIES | ||
| A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas | Zhi Peng, Beijing, China | 4011 Rapid Oral Abstract Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Monday , June 1 , 202 6 1:15 PM CDT |
| Tumor shrinkage and depth of response with fruquintinib in patients with metastatic colorectal cancer: Results from FRESCO and FRESCO-2 | Elena Elez, Barcelona, Spain | 3555 Poster Session: Gastrointestinal Cancer - Colorectal and Anal |
| Efficacy of fruquintinib plus sintilimab versus axitinib or everolimus by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study | Kaiwei Yang, Beijing, China | 4531 Poster Session: Genitourinary Cancer - Kidney and Bladder |
| Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden | Yuanyuan Qu, Shanghai, China | 4533 Poster Session: Genitourinary Cancer - Kidney and Bladder |
| Association of Palmar-plantar erythrodysesthesia syndrome (PPES), hypothyroidism and clinical outcome in previously treated endometrial cancer (EMC) with pMMR status: A subgroup analysis of FRUSICA-1 | Xiaotian Han, Shanghai, China | e17612 Publication Only: Gynecologic Cancer |
| INVESTIGATOR-INITIATED STUDIES | ||
| Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial | Jianmin Xu , Shanghai, China | LBA3563 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer | Yue Liu, Hangzhou, China | TPS3680 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS trial | Joseph Tintelnot, Hamburg, Germany | TPS3684 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety | Chang Wang, Changchun, China | 2631 Poster Session : Developmental Therapeutics - Immunotherapy |
| Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS-mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study | Yun Xu, Shanghai, China | 35 28 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC) | Wenhua Li, Shanghai, China | 3534 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases | Mengzhou Guo, Shanghai, China | 35 52 Poster Session : Gastrointestinal Cancer - Colorectal and Anal |
| Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study | Xiaodong Zhu, Shanghai, China | 4063 Poster Session : Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Phase II study of utidelone plus fruquintinib for the treatment of platinum-resistant recurrent ovarian cancer (FRUTD trial) | Hao Wen, Shanghai, China | 5579 Poster Session : Gynecologic Cancer |
| Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study | Wangjun Liao, Guangzhou, China | e15539 Publication Only: Gastrointestinal Cancer - Colorectal and Anal |
| Intermittent fruquintinib plus trifluridine/tipiracil in refractory metastatic colorectal cancer (mCRC): A single-center, single-arm phase II study | Yifu He/ Jiayu Niu, Hefei, China | e15560 Publication Only: Gastrointestinal Cancer - Colorectal and Anal |
| Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer | Qian Li, Nanning, China | e15571 Publication Only: Gastrointestinal Cancer - Colorectal and Anal |
| Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial | Wei Li, Suzhou, China | e15583 Publication Only: Gastrointestinal Cancer - Colorectal and Anal |
| Real-world use of fruquintinib in refractory metastatic colorectal cancer in the United States | Vasu Bansal, Kansas City, US | e15713 Publication Only: Gastrointestinal Cancer - Colorectal and Anal |
| Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase Ib/II study (FUNCTION) | Beibei Chen, Zhengzhou, China | e16033 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study | Yanhong Gu, Nanjing, China | e16070 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma | Xuetao Shi/ Jingtao Zhong, Jinan, China | 4136 Poster Session : Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial | Wenquan Wang, Shanghai, China | 4198 Poster Session : Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial | Huijuan Yang, Shanghai, China | 5586 Poster Session : Gynecologic Cancer |
| Surufatinib for advanced or metastatic chemotherapy-refractory thymic epithelial tumor: A single-arm, single-center, phase II study | Bei Xu, Shanghai, China | 8119 Poster Session : Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers |
| Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study | Fuxiang Zhou, Wuhan, China | e16172 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Efficacy and safety of surufatinib combined with immune checkpoint inhibitors plus chemotherapy in patients with biliary tract cancers: A real-world study | Shasha Fan, Changsha, China | e16222 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary |
| Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung cancer with low level gene copy number MET: A multi-center, open-label, and phase 2 study | Xiang Han, Qingdao, China | e20079 Publication Only: Lung Cancer - Non-Small Cell Local-Regional/ Small Cell/Other Thoracic Cancers |
Medical Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.